| Megan L Krause, MD | |
|
3901 Rainbow Blvd, 5026 Wescoe, Mail Stop 2026, Kansas City, KS 66160-8500 | |
| (913) 588-6009 | |
| Not Available |
| Full Name | Megan L Krause |
|---|---|
| Gender | Female |
| Speciality | Rheumatology |
| Experience | 15 Years |
| Location | 3901 Rainbow Blvd, Kansas City, Kansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811126972 | NPI | - | NPPES |
| ENROLLED | Medicaid | MN | |
| ENROLLED | Medicaid | IA | |
| P01021799 | Other | MN | MEDICARE RAILROAD |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Kansas Hospital | Kansas city, KS | Hospital |
| University Of Kansas Health System - St Francis Campus | Topeka, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kansas University Physicians, Inc. | 8921911587 | 1456 |
| Kansas University Physicians, Inc. | 8921911587 | 1456 |
News Archive
Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that GSK has initiated its second pivotal Phase 3 trial to evaluate the efficacy of long-term treatment with the investigational Lp-PLA2 inhibitor darapladib in men and women with acute coronary syndrome (ACS).
Kaiser Health News reports that advocates of the health law, which is under renewed attack by Republicans after the mid-term election, are "huddling … in an effort to thwart GOP efforts" to overturn the law. "Groups that back the law aren't likely to coalesce around a single message to increase public support. Some patient groups, for example, are likely to try to steer clear of partisan politics and focus instead on promoting the law and pressing for its full implementation.
The American Brain Tumor Association has launched a new Special Projects Discovery Grant program to support fresh and creative research ideas for solving the challenges of brain tumor diagnosis and treatment.
Have scientists uncovered the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Achille's heel? New preclinical research from Cell neutralizing antibodies targeting the N-terminal domain of the coronavirus could be a potential target for antibodies to bind and effectively neutralize SARS-CoV-2.
When Jose Palacios arrived to the operating room at NYU Langone Hospital–Brooklyn last March, he thought he might never walk again. The infection in his foot had gotten so bad his doctor told him amputation may be necessary. But when the surgery was over, he could hardly believe his eyes.
› Verified 1 days ago
| Entity Name | Kansas University Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003858333 PECOS PAC ID: 8921911587 Enrollment ID: O20040401000328 |
News Archive
Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that GSK has initiated its second pivotal Phase 3 trial to evaluate the efficacy of long-term treatment with the investigational Lp-PLA2 inhibitor darapladib in men and women with acute coronary syndrome (ACS).
Kaiser Health News reports that advocates of the health law, which is under renewed attack by Republicans after the mid-term election, are "huddling … in an effort to thwart GOP efforts" to overturn the law. "Groups that back the law aren't likely to coalesce around a single message to increase public support. Some patient groups, for example, are likely to try to steer clear of partisan politics and focus instead on promoting the law and pressing for its full implementation.
The American Brain Tumor Association has launched a new Special Projects Discovery Grant program to support fresh and creative research ideas for solving the challenges of brain tumor diagnosis and treatment.
Have scientists uncovered the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Achille's heel? New preclinical research from Cell neutralizing antibodies targeting the N-terminal domain of the coronavirus could be a potential target for antibodies to bind and effectively neutralize SARS-CoV-2.
When Jose Palacios arrived to the operating room at NYU Langone Hospital–Brooklyn last March, he thought he might never walk again. The infection in his foot had gotten so bad his doctor told him amputation may be necessary. But when the surgery was over, he could hardly believe his eyes.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Megan L Krause, MD 3901 Rainbow Blvd, 5026 Wescoe, Mail Stop 2026, Kansas City, KS 66160-8500 Ph: (913) 588-6009 | Megan L Krause, MD 3901 Rainbow Blvd, 5026 Wescoe, Mail Stop 2026, Kansas City, KS 66160-8500 Ph: (913) 588-6009 |
News Archive
Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that GSK has initiated its second pivotal Phase 3 trial to evaluate the efficacy of long-term treatment with the investigational Lp-PLA2 inhibitor darapladib in men and women with acute coronary syndrome (ACS).
Kaiser Health News reports that advocates of the health law, which is under renewed attack by Republicans after the mid-term election, are "huddling … in an effort to thwart GOP efforts" to overturn the law. "Groups that back the law aren't likely to coalesce around a single message to increase public support. Some patient groups, for example, are likely to try to steer clear of partisan politics and focus instead on promoting the law and pressing for its full implementation.
The American Brain Tumor Association has launched a new Special Projects Discovery Grant program to support fresh and creative research ideas for solving the challenges of brain tumor diagnosis and treatment.
Have scientists uncovered the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Achille's heel? New preclinical research from Cell neutralizing antibodies targeting the N-terminal domain of the coronavirus could be a potential target for antibodies to bind and effectively neutralize SARS-CoV-2.
When Jose Palacios arrived to the operating room at NYU Langone Hospital–Brooklyn last March, he thought he might never walk again. The infection in his foot had gotten so bad his doctor told him amputation may be necessary. But when the surgery was over, he could hardly believe his eyes.
› Verified 1 days ago
Micholee Beth Polsak, DO Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, 6040 Delp, Ms 1020, Kansas University Physicians Inc, Kansas City, KS 66160 Phone: 913-588-3974 Fax: 913-588-6055 | |
Ira William Marsh, MD Rheumatology Medicare: May Accept Medicare Assignments Practice Location: 8929 Parallel Pkwy, Kansas City, KS 66112 Phone: 913-596-4000 | |
Dr. Tara L Lin, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-6030 Fax: 913-588-4085 | |
Kristin N Fee, D.O. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd # Ms 2027, Kansas City, KS 66160 Phone: 913-588-3974 Fax: 913-588-6055 | |
Donald J. Mcsweyn, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 8919 Parallel Pkwy, Suite 580, Kansas City, KS 66112 Phone: 913-596-7224 Fax: 913-596-7257 | |
Dr. Dhanunjaya Lakkireddy, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Suite#g600, Kansas City, KS 66160 Phone: 913-588-9600 Fax: 913-588-9770 | |
Archana Pareek, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, 6040 Delp, Ms 1020, Division Of General And Geriatric Medicine, University, Kansas City, KS 66160 Phone: 913-588-6005 Fax: 913-588-3877 |